FDA
-
-
-
-
-
-
-
Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)
-
-
-
-
-
-
-
Lantheus completes sale of SPECT business to SHINE Technologies
-
-
-
-
-
-
-
Lantheus Announces FDA Acceptance of New Drug Application for MK-6240, a PET Imaging Agent Targeting Tau in Alzheimer’s Disease
-
-
-
-
-
-
-
Lantheus completes Life Molecular Imaging acquisition, names new R&D head
-
-
-
-
-
-
-
Lantheus Announces Sale of SPECT Business to SHINE Technologies
-
-
-
-
-
-
-
Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader
-
-
-
-
-
-
-
Lantheus to Present Additional Clinical Data from Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024
-
322,084 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

